Inhalable Drug Delivery
This article was originally published in Start Up
Executive Summary
Over the past few years, the drug delivery industry has seen a major change in its basic structure. Nowhere is this more true than in the subsegment of inhalable drug delivery. One of the big drivers of the change: drug delivery companies angling for market share in partnering.
You may also be interested in...
Activaero GMBH
Specializing in controlled breathing technologies for inhaled drug delivery Activaero GMBH is developing a suite of technologies that can efficiently deliver personalized dosing to different targets in the lungs. Activaero is seeking partners with dose-critical or expensive drugs that will benefit from the technology's dose-sparing benefits, or drugs that previously couldn't be delivered using the pulmonary route
Inhale Chooses the Service Path
Drug delivery has seen plenty of acquisitions-but they represent two basic philosophical approaches, represented most recently by Johnson & Johnson's purchase of Alza and Inhale's acquisition of two privately-held firms, Bradford and Shearwater. The basic question: can a service model bring significant returns to a large shareholder base or will Alza's evolution into a product company define the way forward for the industry?
Intranasal Technology Inc.
Intranasal Technology Inc. will reformulate established, FDA-approved oral and injectable drugs into new versions for nasal delivery.